Riskpilot← Back to searchSign inGet full accessSelma Diagnostics ApS
APSActiveCVR 36961376Diplomvej 378, st.Research and experimental development on natural sciences and engineering · NACE 7210Est. 20151 employees
Revenue 2024
DKK -1,4M
-5% vs 2023
EBITDA margin
178.6%
0% vs 2023
Equity ratio
-811.0%
Financial strength
Net profit 2024
DKK -2,2M
-13% vs 2023
| Revenue | DKK -1,4M | -5% |
| EBITDA | DKK -2,4M | +0% |
| Net profit | DKK -2,2M | -13% |
| Total assets | DKK 998K | -9% |
| Equity | DKK -8,1M | -37% |
| Employees | 1 | — |
Legal name
Selma Diagnostics ApS
CVR number
36961376
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
10. juli 2015
Share capital
DKK 169.091
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af 2 bestyrelsesmedlemmer i forening eller 1 bestyrelsesmedlem i forening
med 1 direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive virksomhed med udvikling og markedsføring af diagnoseteknologi samt anden virksom-hed, der står i forbindelse hermed.
Address
Diplomvej 378, st.
Phone
+4551947259
Email
ak@selmadiagnostics.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -266 | -1.928 | -1.663 | -1.931 | -1.617 | -1.844 | -1.636 | -1.428 | -1.363 |
| Staff expenses | -596 | -902 | -1.632 | -1.591 | -1.382 | -814 | -1.071 | -1.015 | -1.071 |
| EBITDA | -862 | -2.830 | -3.295 | -3.522 | -2.999 | -2.658 | -2.707 | -2.443 | -2.433 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -30 | -65 | -60 | -67 | -75 |
| EBIT | -862 | -2.830 | -3.295 | -3.522 | -3.029 | -2.724 | -2.767 | -2.510 | -2.508 |
| Net financials | -46 | -56 | -6 | -3 | -9 | -3 | -1 | -8 | -326 |
| Profit before tax | -907 | -2.886 | -3.301 | -3.525 | -3.038 | -2.727 | -2.768 | -2.518 | -2.835 |
| Tax | -190 | -635 | -713 | -775 | -658 | -773 | -0 | -591 | -656 |
| Net profit | -718 | -2.251 | -2.589 | -2.750 | -2.380 | -1.954 | -2.768 | -1.927 | -2.178 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 209 | 4.175 | 1.904 | 1.261 | 1.454 | 2.041 | 516 | 1.099 | 998 |
| Equity | -655 | 4.102 | 1.513 | 415 | 733 | -1.221 | -3.989 | -5.916 | -8.094 |
| Long-term debt | 841 | 0 | 0 | 42 | 58 | 58 | 59 | 62 | 64 |
| Short-term debt | 24 | 73 | 391 | 804 | 663 | 3.204 | 4.446 | 6.952 | 9.028 |
| Total debt | 865 | 73 | 391 | 846 | 721 | 3.261 | 4.505 | 7.014 | 9.092 |
EBITDA margin
-243316900.0%
This company
15.8%
Market median
-1539980480% vs market
20162024
Equity ratio
-811.0%
This company
38.2%
Market median
-2223% vs market
20162024
Return on equity
-217840000.0%
This company
18.4%
Market median
-1183913143% vs market
20162024
Net profit margin
-217840000.0%
This company
8.1%
Market median
-2689382816% vs market
20162024
Asset turnover
-1.37×
This company
1.12×
Market median
-222% vs market
20162024
Debt / equity
1.12×
This company
0.62×
Market median
-81% vs market
20162024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2015-07-10 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AH Chief Executive Officer | Chief Executive Officer | 2015 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
CARSTEN GOMARD HOLDING ApS | Company | 50.0% | 50.0% | 2020 |
| Individual | 10.0% | 10.0% | 2020 | |
Kunding Holding ApS | Company | 10.0% | 10.0% | 2020 |
Selma Diagnostics ApS | Company | 5.0% | 5.0% | 2020 |
Flaneur Invest 1 ApS | Company | 5.0% | 5.0% | 2017 |
| Individual | 25.0% | 25.0% | 2015 | |
| Individual | 5.0% | 5.0% | 2017 | |
| Individual | 25.0% | 25.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
CARSTEN GOMARD HOLDING ApS
Selma Diagnostics ApS Board members of Selma Diagnostics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andreas Hjarne Kunding | Chief Executive Officer | 0 companies |
| Carsten Krogh Gomard | Chairman | 0 companies |